Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Magnesium→

Magnesium Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
7439-95-4
Molecular formula
Mg
Molecular weight
24.305 g/mol
Drug class
Essential divalent electrolytemagnesium replacement
Mechanism of action
Acts as a cofactor for hundreds of enzymes and is required for ATP-dependent reactions, neuromuscular transmission, membrane stability, potassium and calcium homeostasis and normal cardiac electrophysiology.
Indications / reported uses
  • Prevention and treatment of magnesium deficiency or hypomagnesaemia using an appropriate oral or parenteral magnesium salt; indication and dose depend on the salt, route and clinical setting

Sources: NIH Office of Dietary Supplements — Magnesium fact sheet · NHS — Magnesium · FDA product information

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Essential divalent electrolyte; magnesium replacement

Mechanism of action

Acts as a cofactor for hundreds of enzymes and is required for ATP-dependent reactions, neuromuscular transmission, membrane stability, potassium and calcium homeostasis and normal cardiac electrophysiology.

General use cases

  • Prevention and treatment of magnesium deficiency or hypomagnesaemia using an appropriate oral or parenteral magnesium salt; indication and dose depend on the salt, route and clinical setting

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Magnesium Environmental Risk Assessment (ERA) (the Magnesium ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.